| Cat. No. |
CRP0894 |
| Product Overview |
Recombinant human TPO
produced in CHO, consisting of a 332 amino acid residue with a
predicted molecular mass of approximately 35 kDa, migrates with an
apparent molecular mass of 80±10 kDa in SDS-PAGE as a result of
glycosylation. |
| Description |
Thrombopoietin (Tpo),
the ligand for the receptor encoded by the c-Mpl proto-oncogene, is
a key regulator of megakaryocytopoiesis and hrombopoiesis in vitro
and in vivo. The cDNAs for Tpo have recently been cloned from
canine, murine and human sources. The proteins from these three
species are highly conserved, exhibiting from 69-75% sequence
identity at the amino acid level. Human Tpo cDNA encodes a 353 amino
acid residue protein with a 21 amino acid residue signal peptide
that is cleaved to yield the 332 amino acid residue mature protein.
Two distinct domains, separated by a pair of arginine residues that
may be a proteolytic cleavage site, have been identified in Tpo: the
amino terminal region exhibiting sequence homology to erythropoietin
and the carboxy terminal region containing multiple potential
N-linked glycosylation sites. Recombinant Tpo has now been shown to
stimulate the maturation, as well as the proliferation, of
megakaryocytes and may have important therapeutic applications for
the treatment of various clinical conditions associated with
thrombocytopenia. |
| Purity |
>98% by SDS-PAGE and
HPLC analyses. |
| Specific Activity |
Fully biologically
active when compared to standard. The ED50 as determined by the
dose-dependant stimulation of Mo7e cells is typically 1-3 ng/ml,
corresponding to a Specific Activity of 1 x 106 IU/mg. |
| Physical Appearance |
Sterile Filtered
White lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a
0.2μm filtered concentrated (1mg/ml) solution in PBS, pH 7.4. |
| Endotoxin |
Less than 1EU/μg of
rHuTPO a as determined by LAL method. |
| Reconstitution |
We recommend that
this vial be briefly centrifuged prior to opening to bring the
contents to the bottom. Reconstitute in sterile distilled water or
aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0
mg/ml. Stock solutions should be apportioned into working aliquots
and stored at ≤20°C. Further dilutions should be made in appropriate
buffered solutions. |
| Storage |
This lyophilized
preparation is stable for several weeks at 2-8°C, but should be kept
at -20°C for long term storage, preferably desiccated. Upon
reconstitution, the preparation is stable for up to one week at
2-8°C. For maximal stability, apportion the reconstituted
preparation into working aliquots and store at -20°C to -70°C. Avoid
repeated freeze/thaw cycles. |
| Gene Information
|
Gene Name |
THPO |
|
Synonyms |
Megakaryocyte colony-stimulating
factor; Myeloproliferative leukemia virus
oncogene ligand; C-mpl ligand; ML; Megakaryocyte growth and
development factor; MGDF; TPO; MKCSF; ML; MPLLG; MGC163194; Leukemia
virus oncogene ligand; thrombopoietin;MPL ligand;c-mpl ligand;
thrombopoietin nirs variant 1; megakaryocyte stimulating factor |
|
GeneID |
7066 |
|
mRNA Refseq |
NM_199228 |
|
Protein Refseq |
NP_954698 |
|
MIM |
600044 |
|
UniProt ID |
P40225 |
|
Chromosome Location |
3q27 |
|
Pathway |
Hematopoietic cell lineage |
|
Function |
cytokine activity ;
growth factor activity; hormone activity |
|
.jpg) |
Download Datasheet
 |
|
PDB rendering based on 1v7m. |
|